Join the Talzenna group to help and get support from people like you.
Talzenna News
FDA Approves Talzenna for Metastatic, Castration-Resistant Prostate Cancer
MONDAY, June 26, 2023 – The U.S. Food and Drug Administration has approved Talzenna (talazoparib) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic...
Pfizer’s Talzenna (talazoparib) in Combination with Xtandi (enzalutamide) Receives U.S. FDA Approval for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
NEW YORK--(BUSINESS WIRE) June 20, 2023 – Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase...
ASCO: Drug Combo Ups Progression-Free Survival for Metastatic Prostate Cancer
THURSDAY, June 8, 2023 – For patients with metastatic castration-resistant prostate cancer (mCRPC), talazoparib plus enzalutamide results in improvement in radiographic progression-free survival...
FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
On October 16, 2018, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Prostate Cancer, Breast Cancer